Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01237-22
Abstract: The antituberculosis candidate OPC-167832, an inhibitor of DprE1, was active against Mycobacterium abscessus. Resistance mapped to M. abscessus dprE1, suggesting target retention. ABSTRACT The antituberculosis candidate OPC-167832, an inhibitor of DprE1, was active against Mycobacterium… read more here.
Keywords: opc 167832; dpre1; mycobacterium abscessus; mycobacterium ... See more keywords
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
Sign Up to like & getrecommendations! Published in 2023 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01477-22
Abstract: OPC-167832, an inhibitor of decaprenylphosphoryl-β-d-ribose 2’-oxidase, demonstrated potent antituberculosis activity and a favorable safety profile in preclinical studies. This report describes the first two clinical studies of OPC-167832: (i) a phase I single ascending dose… read more here.
Keywords: single ascending; opc 167832; ascending dose; activity ... See more keywords